Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
London-listed Poolbeg Pharma has received regulatory approval in the UK to proceed with human clinical trials of its influenza drug POLB 001. The company, which spun out from Dublin-listed pharmaceutical
AI is an advanced form of machine learning that can rapidly analyse very large datasets, highlight non-intuitive trends resulting in the identification of novel disease targets and associated drugs. AI
Poolbeg Pharma plc (LON:POLB’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma PLC said on Monday that its partner OneThree Biotech has completed optimizing its artificial intelligence model to identify treatments for respiratory syncytial virus, with results expected in the
Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, says its artificial intelligence (AI) partner, OneThree Biotech, Inc., has completed the build and optimization of a tailored AI model of
Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that, further to its announcement in February 2022, Artificial Intelligence partner OneThree Biotech, Inc.,
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
